[Clinico-pharmacological study of a new Russian anti-angina preparation dinitrosorbilong].
Eighty patients with ischemic heart disease and stable angina pectoris of effort were examined for the efficacy of dinitrosorbilong (DNL), a new long-acting drug based on isosorbide dinitrate (ID). The anti-ischemic effect of DNL appraised with the aid of repeated exercise lasted about 8h, which was on the average 4 h longer as compared with the duration of the anti-ischemic effect of ID tablets. The regular intake of DNL favoured an appreciable decrease in the number of angina pectoris attacks making it possible to lower nitroglycerin consumption. DNL was well tolerated by the patients.
D000284:Administration, Oral; D000787:Angina Pectoris / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D003331:Coronary Vessels / Q000187:drug effects*; D004343:Drug Implants; D005080:Exercise Test; D005881:Gingiva; D006801:Humans; D007548:Isosorbide Dinitrate / Q000627:therapeutic use*; D005996:Nitroglycerin / Q000627:therapeutic use
D004343:Drug Implants; D005996:Nitroglycerin; D007548:Isosorbide Dinitrate
Kliniko-farmakologicheskoe izuchenie novogo otechestvennogo antianginal'nogo preparata dinitrosorbilonga.